Bessemer Group’s PDL BioPharma, Inc. PDLI Stock Holding History

Bessemer Group’s Portfolio PDLI Stock Details PDLI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q4	–	Sell	-21,800	Closed	-$57K	–	2138
2018 Q3	$57K	Buy	+21,800	New	+$53.5K	﹤0.01%	1242
2015 Q3	–	Sell	-274,880	Closed	-$1.77M	–	1858
2015 Q2	$1.77M	Hold	274,880	–	–	0.01%	450
2015 Q1	$1.93M	Buy	274,880 +52,280	+23%	+$379K	0.01%	418
2014 Q4	$1.72M	Buy	+222,600	New	+$1.76M	0.01%	404

Other funds holding PDLI

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

KCM

Kennedy Capital Management St Louis, Missouri $4.72B AUM 36.69% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Connor, Clark & Lunn Investment Management (CC&L) Vancouver, British Columbia, Canada $43.4B AUM 51.29% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

BIP

Brandes Investment Partners La Jolla, California $14.1B AUM 25.52% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Bessemer Group's PDLI Position: Q4 2018 in Review

Bessemer Group sold out of PDL BioPharma, Inc. (PDLI) in Q4 2018, closing a stake of 21,800 shares — an estimated $57K sold.

Bessemer Group first reported a position in PDLI in Q4 2014 and held it in 4 quarters. The position peaked at $1.93M in Q1 2015. 154 funds tracked by Wall St. Rank hold PDLI as of Q4 2018.

Bessemer Group reported no remaining PDL BioPharma, Inc. position as of Q4 2018 after selling out during the quarter.
Bessemer Group sold 21,800 PDL BioPharma, Inc. shares in Q4 2018, an estimated $57K.
Bessemer Group first reported a position in PDL BioPharma, Inc. in Q4 2014 and held it in 4 quarters.
Bessemer Group's PDL BioPharma, Inc. position peaked at $1.93M in Q1 2015.
154 funds tracked by Wall St. Rank held PDL BioPharma, Inc. as of Q4 2018.

Based on Bessemer Group's 13F filing for Q4 2018, filed 12 Feb 2019.